Abstract
The aim of this work is to review current publications on the non-antibacterial effects of macrolides. Macrolides are among the most widely prescribed broad-spectrum antibacterial drugs, especially in patients with respiratory infections. It is now recognized that drugs of this group, in particular azithromycin, also have an immunomodulatory effect, which leads to their therapeutic effect not only in infectious but in other chronic inflammatory diseases also. However, the frequent and prolonged use of macrolides in the treatment of respiratory tract diseases, and recently azithromycin in the treatment of COVID-19, has led to an increase in bacterial resistance to antibiotics of this group. Results: it was shown that one of the key aspects of the development of chronic inflammation of the respiratory tract (for instance, chronic obstructive pulmonary disease) is the loss of the protective epithelial barrier due to the effects of pathogens and pollutants. Azithromycin has been shown to enhance the barrier properties of airway epithelial cells over time, which makes an important contribution to its therapeutic effectiveness. The main non-antibacterial effects of macrolides are considered, which in the future can be applied in treatment of inflammatory diseases associated with airway epithelium damage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
